Edgewise Therapeutics announced promising preclinical and early clinical results for EDG-7500, a novel cardiac drug targeting the Regulatory Light Chain to improve heart relaxation without impairing contraction. This first-in-class treatment aims to address symptomatic hypertrophic cardiomyopathy (HCM), a genetic heart disease causing thickened heart muscle and impaired relaxation. The company plans to start a Phase 3 trial in late 2026 following a successful Phase 2 trial showing safety and no significant impact on heart pumping function. A detailed scientific publication and a webcast discussion are scheduled to provide further insights into EDG-7500's mechanism and potential benefits.
Edgewise Therapeutics' cardiac drug EDG-7500 is highlighted here with Pluang's Health sector market data as context. For readers following Health stocks, as of Sep 22, 2026 17:11 WIB, 41 of 95 priced US Health-sector stocks rose and 44 fell. Notable movers include ACB at USD 3.99 with a -0.99% change and 100% buy order activity, NVAX at USD 10.31 with a -0.96% change and 98% sell order activity, and WGS at USD 97.00 with a -0.85% change and 100% buy order activity.
Australian brand STYLD. has partnered with Mattel to release a limited-edition Barbie-themed Christmas collection featuring summer-inspired, reusable entertaining items in Candy Cane Pink and Peppermint Green. The collection includes insulated carafe...
Kirby McInerney LLP is investigating Fervo Energy for potential securities law violations following the company's Q2 2026 earnings report and a critical research report. Fervo's shares fell sharply after it disclosed possible transmission issues at i...
Airbnb reports a surge in fall travel, with 60% of Americans planning weekend getaways, especially families with infants. Gen Z is driving a trend called lore-tripping, seeking unique local stories, while sports fans engage in groundhopping to iconic...
Solana (SOL) saw a 2.40% price increase within one hour, reaching $105 at 9:54 p.m. ET Monday, driven by $510,000 in short liquidations on Binance, Bybit, and OKX. This surge contrasts with only $10,000 in long liquidations during the same period. De...
On October 12, U.S. spot exchange-traded funds (ETFs) tracking Hyperliquid (HYPE) experienced a combined net outflow of $2.3457 million, with the Bitwise Hyperliquid ETF (BHYP) responsible for the entire withdrawal. Despite this, BHYP's cumulative ne...
